The Boehringer Ingelheim group is one of the world's 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Boehringer Ingelheim is a pioneer in industrial biotechnology. With a workforce of more than 2,000 employees at our sites in Austria and Germany we have world leading facilities dedicated to the development and production of biopharmaceuticals using mammalian cells, microorganisms and yeast as host organisms.
In microbial fermentation, we use the most modern technologies for production, coupled with state-of-the-art extraction and purification procedures in fermentation scales up to 6,000 litres and with a total capacity of about 12,000 litres. Besides interferons, various proteins, scaffolds and antibody fragments, we also manufacture plasmid DNA for gene therapy on a commercial scale. In mammalian cell culture we are Europe's leading manufacturer for therapeutic proteins and monoclonal antibodies with a total capacity of 180,000 litres. In addition we have state-of-the-art development facilities including a 2,000 litres pilot plant for production of clinical trial material. We offer the entire process chain from genetic engineering to the therapeutic drug product including fill & finish and worldwide registration.
All our development and manufacturing processes are conducted according to GMP standards. To date we have registered biopharmaceuticals with the European, Canadian, Japanese and US regulatory authorities. We have generated many successful long-term partnerships in biopharmaceutical production with the world's leading pharmaceutical and biopharmaceutical companies.
Please fill out your name and email address to send an inquiry to the contact listed above.